Sustained delivery of interferons by Micro and Nanosystems

Recent Patents on Materials Science

Volumn 2, Issue 1, 2009, Pages 32-42

  Feczkó, Tivadar ^a,b  

^a CHEMICAL RESEARCH CENTER   (Hungary)

^b UNIVERSITY OF PANNONIA   (Hungary)

Author keywords

Administration; Gel; Interferon; Liposome; Nano and microparticle; Polymer; Sustained delivery

Indexed keywords

GELS; GLYCOPROTEINS; INTERFERONS; LIPOSOMES; MANAGEMENT; NANOMAGNETICS; NANOPARTICLES; NANOSYSTEMS; NUCLEIC ACIDS; PATENTS AND INVENTIONS; POLYMERS;

COMMERCIAL PRODUCTS; FUTURE IMPROVEMENTS; MAGNETIC NANO-PARTICLES; MICRO AND NANO-PARTICLE; MICRO PARTICLES; PARTICULATE DELIVERY SYSTEMS; POLY LACTIC-CO-GLYCOLIC ACID; SUSTAINED DELIVERY;

ANTIBIOTICS;

EID: 77951191121     PISSN: 18744648     EISSN: 18744656     Source Type: Journal    
DOI: 10.2174/1874464810902010032     Document Type: Review

References (63)

1. Brassard DL, Grace MJ, Bordens RW. Interferon- as an immunotherapeutic protein. J Leukoc Biol 2002; 71: 565-581.
2. Chevaliez S, Pawlotsky JM. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 2007; 59(12): 1222-1241.
3. Kuroda, S., Tanizawa, K., Kondo, A., Ueda, M., Seno, M., Tada, H.: EP1491216 (2004).
4. Gresser I, Belardelli F. Endogenous type I interferon as a defence against tumor. Cytokine Growth Factor Rev 2002; 13(2): 111-118.
5. Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 2007;18(5-6): 459-471.
6. Chiellini E, Chiellini EE, Chiellini F, Solaro R. Targeted administration of proteic drugs I. Preparation of polymeric nanoparticles. J Bioact Compat Polym 2001; 16: 441-465.
7. Sanchez A, Tobio M, Gonzalez L, Fabra A, Alonso MJ. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci 2003; 18: 221-229.
8. Van Slooten ML, Boerman O, Romoren K, et al. Liposomes as sustained release system for human interferon-: Biopharmaceutical aspects. Biochim Biophys Acta 2001; 1530: 134-145.
9. Hamidi M, Zarrin A, Foroozesh M. Novel delivery systems for interferons. Crit Rev Biotechnol 2007; 27: 111-127.
10. Shah, S., Khachatouri, A.: WO01041735 (2001).
11. Mathiowitz, E., Webber, W.L., Thanos, C.: US20036531154 (2003).
12. Deluca, P., Jiang, G., Woo, B.: WO2004084819 (2004).
13. Jin, T., Zhu, H., Zhu, J.: US20066998393 (2006).
14. Wright, S.G., Christenson, T., Yeoh, T.Y., Rickey, M.E., Hotz, J.M., Kumar, R., Fineman, M., Smith, C., Ong, J., Lokensgard, D. M., Costantino, H.R.: WO2005110425 (2005).
15. Jon, S.Y., Jeon, Y.J., Oh, D.H., Selvapalam, N.: WO2005010004 (2005).
16. Shah, S., Dai, W.: WO00038651 (2000).
17. Thuresson, K., Tiberg, F., Johansson, M., Harwigsson, I., Joabsson, F.: US20080085263 (2008).
18. Rathi, R.C., Zentner, G.M., Jeong, B.: US20016201072 (2001).
19. Gower, L.B., Olszta, M.J., Douglas, E.P., Munisamy, S., Wheeler, D.L.: WO2005081699 (2005).
20. Mooney, D.J., Shea, L.D., Peters, M.C., Liao, E., Richarson, T.P.: WO01035932 (2001).
21. Rosenberger, V., Moldavski, N., Flashner-barak, M., Lerner, I.E.: WO2005041933 (2005).
22. Shechter, Y., Fridkin, M., Tsubery, H.: WO2004089280 (2004).
23. Dékány, I., Szekeres, M., Pallai, Z., Bali, L.: WO2008107729 (2008).
24. Cohen, S., Freeman, I.: WO2007043050 (2007).
25. Hosheng, T.U., Sung, H.-W.: WO2006073950 (2006).
26. Byun, Y., Yoon, J.H.: WO2004028406 (2004).
27. Chu, G.H., Ogawa, Y., Mcpherson, J.M., Ksander, G., Pratt, B., Hendricks, D., Mcmullin, H.: EP048541 (1995).
28. Tan, H.M., Ming, Y.E., Mcgrath, T.F., Johnston, K.A., Micalizzi, M., Mckenna, P., Redmon, M.P., Vuppala, M.K., Musso, G.F.: WO2007021970 (2007).
29. King, T.W., Patrick J.C.: US20077291348 (2007).
30. Mcginity, J.W., Iwata, M.: US5288502 (1994).
31. Jin, T., Zhu, H., Zhu, J.: WO03101600 (2003).
32. Lokensgard, D.M. WO2005102293 (2005).
33. Dulieu, C., Richard, J., Benoit, J.-P.: US20056967028 (2005).
34. Maskiewicz, V.K., Prestrelski, S.J., Smith, J.G., Huang, M.T.: US20046730328 (2004).
35. Taylor, D., Mcclain, J., Smoke, C., Cole, M., Deyoung, J.: WO2007011707 (2007).
36. Shah, S.: WO039846212 (2003).
37. Zhang, Y., Urian, C. R.: WO007412 (1998).
38. Rao, K.K.: WO2007113665 (2007).
39. Sengupta, S., Zhao, G., Capila, I., Eavarone, D., Sasisekharan, R.: WO2008014478 (2008).
40. Pai, C.-M., Min, M.-H., Hwang, J.-S., Cho, K.-M.: WO2005061004 (2005).
41. Dubrow, R.S., Bock, L.A., Daniels, H. R., Hardev, V.D., Niu, C., Sahi, V.: WO2007078304 (2007).
42. Ham, S.-J., Suh, J.-S., Huh, Y.-M., Yoon, H.-G., Goyang, G.-D., Yang, J.-M.: WO2007097593 (2007).
43. Liu, J., Johnston, M. R., Xiao, Y. W.: WO2007019678 (2007).
44. Koritala, P.R., Koritala, S.: WO2006088473 (2006).
45. Haslam, J.L., Higuchi, T., Mlodozeniec, A.R.: EP0126684 (1991).
46. Chen, G., Houston, P.R., Kleiner, L., Spaltro, J.: WO03041757 (2003).
47. Drapeau, S.J., Mckay, W.F.: WO2008089164 (2008).
48. Chen, G., Priebe, D.T.: WO2005049069 (2005).
49. Haslam, J.L., Higuchi, T., Mlodozeniec, A.R.: US4474751 (1984).
50. Schultz, C.: WO2005110473 (2005).
51. Berry, S., Fereira, P.J., Junnarkar, G., Desjardin, M.A.: WO2004056338 (2004).
52. Kestel, F.A.: WO02032395 (2002).
53. Radhakrishnan, R.: WO90006775 (1990).
54. Breegi, W., Calias, P., Adamis, A.P., Shima, D., Cunningham, E.T.: WO2004073765 (2004).
55. Hansen, H.E., Buch-rasmussen, T., Sabra, M.C.: WO03051328 (2003).
56. Pierce, G., Chandler, L.A.: WO01040272 (2001).
57. Boutin, R.H.: US20006127170 (2000).
58. Dobrovolskaia MA, Mcneil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007; 2(8): 469-478.
59. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54(5): 631-651.
60. Neuberger T, Schöpf B, Hofmann H, Hofmann M, Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater 2005; 293 (1): 483-496.
61. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomater 2005; 26: 3995-4021.
62. Cheon, J.W.: WO2007097605 (2007).
63. Fan SX, Skillman DR, Liao MJ, Testa D, Meltzer MS. Increased efficacy of human natural interferon alpha (IFN-aalpha n3) versus human recombinant IFN-alpha 2 for inhibition of HIV-1 replication in primary human monocytes. AIDS Res Hum Retroviruses 1993; 9: 1115-1122.